BioNTech SE - American Depositary Shares (BNTX)
102.66
-9.80 (-8.71%)
NASDAQ · Last Trade: Sep 8th, 9:38 PM EDT
Pfizer and BioNTech's LP.8.1 COVID-19 vaccine boosts antibodies 4-fold in high-risk adults, with no new safety concerns reported.
Via Benzinga · September 8, 2025
BioNTech and Bristol Myers report strong interim results for pumitamig plus chemo in lung cancer, showing high response rates.
Via Benzinga · September 8, 2025
Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Insidestocktwits.com
Via Stocktwits · September 8, 2025
Summit Therapeutics stock crashed Monday after the company's drug failed to meet the bar for overall survival in lung cancer.
Via Investor's Business Daily · September 8, 2025
Why Did BioNTech Stock Surge 10% Pre-Market Today?stocktwits.com
Via Stocktwits · September 5, 2025
Pfizer, BioNTech Get FDA Clearance For Updated Covid Vaccine In Senior Adults And Younger At-Risk Populationstocktwits.com
Via Stocktwits · August 27, 2025
The company might be close to commercializing its most advanced pipeline program.
Via The Motley Fool · September 5, 2025
Via Benzinga · September 5, 2025
It's unprecedented times for the Covid vaccine market, experts say. And Pfizer and Moderna remain under significant pressure.
Via Investor's Business Daily · September 5, 2025
The company's DualityBio-partnered drug met the pre-specified bar for success in a pivotal study.
Via Investor's Business Daily · September 5, 2025
BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Pushstocktwits.com
Via Stocktwits · August 4, 2025
BioNTech and DualityBio reported Phase 3 success for trastuzumab pamirtecan in HER2 breast cancer, setting stage for regulatory submission in China.
Via Benzinga · September 5, 2025
Daskalakis resigned due to political interference in CDC, fears harm will come from new direction. CDC leaders also resign in protest.
Via Benzinga · September 1, 2025
Marvell, Hormel, and Keurig Dr Pepper led weekly large-cap losers on weak guidance and analyst downgrades.
Via Benzinga · August 31, 2025
FDA approves Pfizer, Moderna, and Novavax Covid vaccines for high-risk groups as emergency authorizations end and vaccines transition to full marketing.
Via Benzinga · August 27, 2025
Shares of one vaccine-maker are under pressure on Robert F. Kennedy Jr.'s move on Wednesday.
Via Investor's Business Daily · August 27, 2025
The Trump administration may remove COVID-19 vaccines from the U.S. market as RFK Jr.'s allies gain influence at HHS, with a new vaccine task force led by a known skeptic.
Via Benzinga · August 25, 2025
This big pharma company's juicy dividend is looking even more attractive.
Via The Motley Fool · August 13, 2025
CDC shooting tied to anti-vaccine beliefs sparks warnings from staff, as leaders clash over the future of mRNA vaccines and federal health policy.
Via Benzinga · August 12, 2025
Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.
Via Benzinga · August 11, 2025
Via Benzinga · August 5, 2025
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance.
Via Benzinga · August 4, 2025
BioNTech Q2 2025 earnings beat revenue estimates with $255.99M, narrowing losses to -$1.57 EPS. Shares rose 2% pre-market as oncology pipeline advances.
Via Chartmill · August 4, 2025